TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

VARENICLINE TARTRATE

VARENICLINE TARTRATE
Approved 2021-08-11
21
Indications
--
Phase 3 Trials
4
Years on Market

VARENICLINE TARTRATE Approval History

Loading approval history...

What VARENICLINE TARTRATE Treats

1 indications

VARENICLINE TARTRATE is approved for 1 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Smoking Cessation
Source: FDA Label

Drugs Similar to VARENICLINE TARTRATE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

VARENICLINE TARTRATE FDA Label Details

Pro

Indications & Usage

Varenicline tablets is indicated for use as an aid to smoking cessation treatment. Varenicline tablets is a nicotinic receptor partial agonist indicated for use as an aid to smoking cessation treatment. ( 1 and 2.1 )

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.